Ramachandran Murali

faculty photo
Department: Pathology and Laboratory Medicine

Contact information
243 John Morgan Bldg.3620 Hamilton Walk
Philadelphia, PA 19104
Office: 215-573-9256
Fax: 215-898-2401
Education:
B.Sc. (Physics)
University of Madras, India, 1978.
M.Sc. (Physics)
University of Madras,India, 1980.
Ph.D. (Biophysics)
University of Madras, India, 1986.
Permanent link
 

Description of Research Expertise

Structural Biology, Cancer Biology and Immunology

Description of Other Expertise

Drug Design

Description of Itmat Expertise

Dr. Murali studies the complex relationship between inherent conformation flexibility in proteins and its function. Also, he is developing methods to discover allosteric drugs that can disable protein complexes and their function.

Selected Publications

Guillemard, V., Nedev, HN., Berezov, A., Murali, R. and Saragovi, U.: HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valaency of the targeting ligand. DNA Cell Biol. 24(6): in press, Jun 2005.

Murali, R., Cheng,X., Berezov, A., Du, X., Schon, A., Freire, E., Xu, X., Chen, Y.H. and Greee, M.I.: Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc Natl Acad Sci U S A 102: 10970-10975, July 2005.

Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H. & Murali, R. : Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J. Biol. Chem 279: 8269-8277, 2004.

Hasegawa A, Cheng X, Kajino K, Berezov A, Murata K, Nakayama T, Yagita H, Murali R*, Greene MI. : Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A 101: 6599-6604, 2004.

Berezov, A., Greene, M. I. & Murali, R. : Structure-Based Approaches to Inhibition of erbB Receptors with Peptide Mimetics Immunol Res 27: 303-308, 2003.

Murali, R., Liu, Q., Cheng, X., Berezov, A., Richter, M., Furuchi, K., Greene, M. I. & Zhang, H. : Antibody like peptidomimetics as large scale immunodetection probes Cell Mol Biol 49: 209-216, 2003.

Kim, N., Ussin, L., Cheng, X., Murali, R. & Sullivan, K. E. : TNFalpha Inhibition in MRL/lpr Mice Ameliorates Pulmonary but not Renal Disease J Autoimmun 19: 215-222. 2002.

Horie, T., Shen, Y., Kajino, K., Gaubin, M., Bonomi, G., Mani, J , Berezov, A., Piatier-Tonneau, D., Guardiola, J., Hillard, B., Rostami, A., Greene, M. I., Murali, R. : Study of disabling T-cell activation and inhibiting T-cell mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidomimetics. Exp. Mol. Pathology 73: 93-97, 2002.

Berezov, A., Chen, J.., Liu, Q., Zhang, H., Greene, M.I. Murali, R : Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics. J. Biol. Chem. 277: 28330-28339, 2002.

Murali, R., Kajino, K., Hasegawa, A., Berezov, A. & Takasaki, W. : Design and Development of small molecule inhibitor of TNF alpha, eds. Ciliberto, G. & Savino, R. (eds.). Marcel Dekker, Inc., New York, NY,(Chapter 5), 133-161, 2001.

back to top
Last updated: 11/21/2013
The Trustees of the University of Pennsylvania